000			03579nam a22003975i 4500
999			_c75871 _d75871 _x1
001			75871
003			ES-MaUEC
005			20230207040200.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			121116s2013 xxua s 001 0 eng d
020			_a9781461446668
024	7		_a10.1007/978-1-4614-4666-8 _2doi
040			_bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC280.B6 _bA38 2013 EB
245	0	0	_aAdvances in Biology and Therapy of Multiple Myeloma _nVolume 1, _pBasic Science _cedited by Nikhil C. Munshi, Kenneth C. Anderson
260			_aNew York _bSpringer International Publishing _c2013
300			_a1 recurso en línea (X, 319 p.) _b34 ilustraciones, 26 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aGenomic strategies determining progressions from MGUS to Multiple Myeloma -- Prognostic implication of Genetic changes (Cytogenetics, and FISH, gains and losses of DNA by SNP array and aCGH) in risk stratification in myeloma -- Advances in MM gene expression profiling -- Growth factors in MM -- Role of Wnt signaling pathways in multiple myeloma pathogenesis -- mTOR pathway in multiple myeloma -- Jak/STAT signaling in the pathogenesis and treatment of multiple myeloma -- Role of extracellular matrix in myeloma biology -- Osteoclasts: Potential target for blocking microenvironmental support of myeloma -- Targeting the BAFF/APRIL cytokine network in multiple myeloma -- Role of Osteoblast in myeloma pathology -- Migration and homing in Multiple Myeloma -- Genes and proteins of myeloma endothelial cells to search specific targets of the tumor vasculature -- Epigenetic regulation of myeloma within its bone marrow microenvironment -- Targeting mulitple myeloma tumor angiogenesis: focus on VEGF -- Novel in vivo model in myeloma -- Index.
520	3		_aDespite the advances in conventional, and novel agent and high dose chemotherapy, multiple myeloma remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in multiple myeloma focusing on the development of molecularly-based novel targeted single-agent and combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. This volume will focus on biology of multiple myeloma, especially on oncogenomic changes, cell signaling pathways and intermediate molecules that are being investigated for development of novel therapies. The book will present newer developments, providing an emphasis on basic science, as well as its significant clinical impact.
988			_aEBOOK, EBSPRINGERrevisado
650		7	_aHuesos _xTumores _9182468 _0comprobar BNE19901362136 _2embne
650		7	_aMieloma múltiple _0comprobar BNE20021387571 _2embne _9160182
700	1		_aMunshi, Nikhil C. _eeditor literario _984566 _0Local
700	1		_aAnderson, Kenneth C. _eeditor literario _946459
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4614-4666-8 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9781461446668
907			_a.b12814891 _b10-10-17 _c01-10-14
942			_2lcc _cLE
945			_aRC280 .B6 A38 2013 EB _cV. 1 _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11544272 _z06-04-17
998			_dz _ea _feng _gxxu _h0